The Lived Experience of Hepatitis C and its Treatment Among Injecting Drug Users: Qualitative Synthesis

Hepatitis C virus infection is a stigmatized condition because of its close association with injecting drug use. There is a need to explore how people who inject drugs (IDUs) perceive hepatitis C, including in relation to treatment experience. We undertook a review, using a qualitative synthesis approach, of English-language qualitative research focusing on the lived experience of hepatitis C among IDUs. The review included 25 published articles representing 20 unique studies. A synthesis of this literature generated three interplaying themes: social stigma, biographical adaptation, and medical and treatment encounters. Interactions with health systems can reproduce stigma linked to drug injecting and hepatitis C, as well as trivialize the lived experience of diagnosis and illness. Hepatitis C can be biographically reinforcing of socially accommodated risk and spoiled identity, as well as disruptive to everyday life. We hypothesize hepatitis C as a liminal illness experience, oscillating between trivial and serious, normalized and stigmatized, public and personal. We conclude by emphasizing the disconnects between the lived experience of hepatitis C among IDUs and Western health care system responses.

[1]  G. Dore,et al.  Treatment for hepatitis C virus infection among current injection drug users in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Manns,et al.  Treatment of chronic hepatitis C with PEGylated interferon and ribavirin , 2002, Current gastroenterology reports.

[3]  B. Edlin,et al.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Fraser,et al.  Public opinion on needle and syringe programmes: avoiding assumptions for policy and practice. , 2007, Drug and alcohol review.

[5]  N. Lintzeris,et al.  The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users , 2008, Harm reduction journal.

[6]  V. Irurita,et al.  Balancing perspective: the response to feelings of being condemned with the hepatitis C virus , 2003 .

[7]  J. Anderson,et al.  Living with a chronic illness: Chinese-Canadian and Euro-Canadian women with diabetes--exploring factors that influence management. , 1995, Social science & medicine.

[8]  D. Sylvestre,et al.  Integrating HCV services for drug users: a model to improve engagement and outcomes. , 2007, The International journal on drug policy.

[9]  S. Zickmund,et al.  Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment , 2006, European journal of gastroenterology & hepatology.

[10]  S. Gifford,et al.  The lived experience of men and women with hepatitis C: implications for support needs and health information. , 2004, Australian health review : a publication of the Australian Hospital Association.

[11]  Allen Zweben Dsw.  Integrating Pharmacotherapy and Psychosocial Interventions in the Treatment of Individuals with Alcohol Problems , 2001 .

[12]  G. Keating,et al.  Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. , 2003, Drugs.

[13]  D. D. Des Jarlais,et al.  HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. , 2007, The International journal on drug policy.

[14]  M. Dunne,et al.  Living with chronic hepatitis C means `you just haven't got a normal life any more' , 2006, Chronic illness.

[15]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[16]  N. Beeching,et al.  Understanding social stigma in women with hepatitis C. , 2004, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[17]  L. Fraenkel,et al.  Patients' experiences related to anti-viral treatment for hepatitis C. , 2006, Patient education and counseling.

[18]  T. Rhodes,et al.  Beyond prevention? Injecting drug user narratives about hepatitis C , 2004 .

[19]  Joan M. Anderson,et al.  Women's perspectives on chronic illness: ethnicity, ideology and restructuring of life. , 1991, Social science & medicine.

[20]  M. Montagne.  APPRECIATING THE USER'S PERSPECTIVE: LISTENING TO THE “METHADONIANS” , 2002, Substance use & misuse.

[21]  Suzanne Bermingham,et al.  HIV‐related discrimination: a survey of New South Wales general practitioners , 1998, Australian and New Zealand journal of public health.

[22]  C. Treloar,et al.  Resilient Coping , 2008, Journal of health psychology.

[23]  Jenny Donovan,et al.  Evaluating meta-ethnography: a synthesis of qualitative research on lay experiences of diabetes and diabetes care. , 2003, Social science & medicine.

[24]  C. Treloar,et al.  The Experience of Interferon-Based Treatments for Hepatitis C Infection , 2005, Qualitative health research.

[25]  B. Edlin,et al.  High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  B. Paterson,et al.  The shifting perspectives model of chronic illness. , 2001, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[27]  C. Treloar,et al.  “Look, I'm fit, I'm positive and I'll be all right, thank you very much”: Coping with hepatitis C treatment and unrealistic optimism , 2008, Psychology, health & medicine.

[28]  Suzanne Robinson,et al.  Consumer participation in the planning and delivery of drug treatment services: the current arrangements. , 2008, Drug and alcohol review.

[29]  C. Treloar,et al.  Chronic Illness Experiences, Clinical Markers and Living with Hepatitis C , 2007, Journal of health psychology.

[30]  Loff,et al.  The Next Plague: Stigmatization and Discrimination Related to Hepatitis C Virus Infection in Australia. , 1997, Health and human rights.

[31]  Simon J Williams,et al.  Chronic illness as biographical disruption or biographical disruption as chronic illness? Reflections on a core concept , 2000 .

[32]  M. Proudfoot.  Comorbid mental disorders and substance use disorders: epidemiology, prevention and treatment , 2004 .

[33]  C. Treloar,et al.  Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. , 2008, Australian health review : a publication of the Australian Hospital Association.

[34]  Kathy Charmaz,et al.  Good days, bad days : the self in chronic illness and time , 1993 .

[35]  H. Spiro.  The Wounded Storyteller: Body, Illness, and Ethics , 1996 .

[36]  T. Rhodes,et al.  Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs. , 2004, Social science & medicine.

[37]  T. Rhodes,et al.  Trust, disruption and responsibility in accounts of injecting equipment sharing and hepatitis C risk , 2008 .

[38]  L. Fraenkel,et al.  What do patients consider when making decisions about treatment for hepatitis C? , 2005, The American journal of medicine.

[39]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[40]  B. Paterson,et al.  The depiction of stigmatization in research about hepatitis C. , 2007, The International journal on drug policy.

[41]  B. Conway,et al.  Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. , 2007, The International journal on drug policy.

[42]  B. Paterson,et al.  Critical analysis of everyday self-care decision making in chronic illness. , 2001, Journal of advanced nursing.

[43]  V. Coates,et al.  Diagnosed with Hepatitis C: a descriptive exploratory study. , 2001, International journal of nursing studies.

[44]  C. Treloar,et al.  Deficit models and divergent philosophies: Service providers’ perspectives on barriers and incentives to drug treatment , 2006 .

[45]  J. Boivin,et al.  Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review , 2008, Journal of Viral Hepatitis.

[46]  K. Dolan,et al.  Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? , 2003, Drug and alcohol review.

[47]  E. Mills,et al.  Therapeutic challenges in hepatitis C-infected injection drug using patients , 2006, Harm reduction journal.

[48]  Carla Treloar,et al.  The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. , 2008, Addiction.

[49]  D. Goldberg,et al.  Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature , 2002, Epidemiology and Infection.

[50]  S. Fraser,et al.  Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications. , 2006, Social science & medicine.

[51]  Peter Vickerman,et al.  Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: An economic modelling report Authors , 2008 .

[52]  M. Russo,et al.  Side effects of therapy for chronic hepatitis C. , 2003, Gastroenterology.

[53]  C. Treloar,et al.  Infection control in the context of hepatitis C disclosure: implications for education of healthcare professionals. , 2004, Education for health.

[54]  Alan Petersen,et al.  The new public health : health and self in the age of risk , 1996 .

[55]  T. Rhodes,et al.  Global estimates of prevalence of HCV infection among injecting drug users. , 2007, The International journal on drug policy.

[56]  R. Garfein,et al.  Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  P. Aggleton,et al.  HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. , 2003, Social science & medicine.

[58]  N. Wright,et al.  Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.

[59]  J. Rehm,et al.  Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of Canada , 2004, Journal of Urban Health.

[60]  J. Pierret.  Interviews and biographical time: the case of long‐term HIV nonprogressors , 2001 .

[61]  C. Banwell,et al.  Australian women's experiences of living with hepatitis C virus: Results from a cross‐sectional survey , 2003, Journal of gastroenterology and hepatology.

[62]  T. Wild,et al.  Everybody's got it, but...: situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada. , 2007, The International journal on drug policy.

[63]  Jean M. Grow,et al.  Breaking the Silence Surrounding Hepatitis C by Promoting Self-Efficacy: Hepatitis C Public Service Announcements , 2008, Qualitative health research.

[64]  M. Bury.  Chronic illness as biographical disruption. , 1982, Sociology of health & illness.

[65]  P. Thuras,et al.  A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. , 2003, Psychosomatics.

[66]  M. Gourevitch,et al.  The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. , 2005, Journal of substance abuse treatment.

[67]  B. Paterson,et al.  Living With the Stigma of Hepatitis C , 2008, Western journal of nursing research.

[68]  É. Roy,et al.  Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montréal. , 2007, The International journal on drug policy.

[69]  J. Kaldor,et al.  High hepatitis C incidence in new injecting drug users: a policy failure? , 2007, Australian and New Zealand journal of public health.

[70]  S. Lenton,et al.  Citizens who inject drugs: the 'Fitpack' study. , 2000, The International journal on drug policy.

[71]  L. Cheever,et al.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[73]  G. Noblit,et al.  Meta-Ethnography: Synthesizing Qualitative Studies , 1988 .

[74]  J. Tritter,et al.  The snakes and ladders of user involvement: Moving beyond Arnstein. , 2006, Health policy.

[75]  S. Fraser,et al.  ‘Spoiled identity’ in hepatitis C infection: The binary logic of despair , 2006 .

[76]  W. von Hippel,et al.  Prejudice among health care workers toward injecting drug users with hepatitis C: does greater contact lead to less prejudice? , 2007, The International journal on drug policy.

[77]  Susan Schultz Kleine,et al.  Variations in Lay Health Theories: Implications for Consumer Health Care Decision Making , 2008 .

[78]  C. Treloar,et al.  Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health co-morbidities , 2008 .

[79]  J. Pierret,et al.  From biographical disruption to biographical reinforcement: the case of HIV‐positive men , 1995 .

[80]  E. Murphy,et al.  Qualitative research methods in health technology assessment: a review of the literature. , 1998, Health technology assessment.

[81]  Gregory M. Herek,et al.  AIDS and Stigma , 1999 .

[82]  Belinda Crockett,et al.  “Eyes Wide Shut”: Narratives of Women Living with Hepatitis C in Australia , 2004, Women & health.